Objective: To investigate the effect of one year treatment with raloxifene on bone mineral density (BMD) and bone turnover markers in postmenopausal women.
Materials and Methods: 75 postmenopausal women with osteoporosis were recruited into study and randomized to raloxifene or control group. Raloxifene group received raloxifene 60 mg, calcium 1000 mg and vitamin-D 800 IU daily. Control group recieved 1000 mg calcium and 800 IU vitamin-D daily. Bone turnover markers as well as BMDs of lumbar spine and femoral neck were evaluated in each group at baseline and after one year of treatment.
Results: 65 patients completed the study. Mean age and mean menopause age of raloxifene group (n=40) were 56 and 45 years respectively; and of control group (n=25) were 62 and 42 years respectively. After 1 year treatment, there was an incease in BMD of lumbar spine (p=0.034) but not that of femoral neck in the raloxifene group. There was no change in levels of bone turnover markers except calcium (p=0.014). There was no change in bone turnover markers and BMDs of the control group. We did not observe any serious adverse event causing withdrawal of medication.
Conclusion: One year treatment with raloxifene 60 mg/day in postmenopausal osteoporosis improves BMD of lumbar spine. Turk J Phys Med Rehab 2006;52:115-8
Key Words: Postmenopausal osteoporosis, raloxifene, bone turnover markers, bone mineral density